Clinical predictors of antipsychotic use in children and adolescents with autism spectrum disorders: a historical open cohort study using electronic health records

European Child and Adolescent Psychiatry

Volumn 25, Issue 6, 2016, Pages 649-658

  Downs, Johnny ^a   Hotopf, Matthew ^a   Ford, Tamsin ^a,c   Simonoff, Emily ^a   Jackson, Richard G ^a,b   Shetty, Hitesh ^b   Stewart, Robert ^a,b   Hayes, Richard D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antipsychotic medications; Autism spectrum disorders; Challenging behaviours; Child and adolescence; Psychiatric comorbidity

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; AGGRESSION; ARTICLE; AUTISM; AUTOMUTILATION; CHILD; COHORT ANALYSIS; COMORBIDITY; CONDUCT DISORDER; DEPRESSION; ELECTRONIC HEALTH RECORD; FEMALE; HUMAN; HYPERKINESIA; ICD-10; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PREDICTOR VARIABLE; PSYCHOSIS; RISK FACTOR; TIC; AUTISM SPECTRUM DISORDER; PREDICTIVE VALUE; PSYCHOLOGY; SELF-INJURIOUS BEHAVIOR; TIC DISORDERS; TRENDS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISM SPECTRUM DISORDER; CHILD; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; SELF-INJURIOUS BEHAVIOR; TIC DISORDERS;

EID: 84944575401     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-015-0780-7     Document Type: Article

References (43)

1. Hsia Y, Wong AYS, Murphy DGM et al (2013) Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology 231:999–1009
2. Coury DL, Anagnostou E, Manning-Courtney P et al (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130:S69–S76
3. Mandell DS, Morales KH, Marcus SC et al (2008) Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics 121:e441–e448
4. Murray ML, Hsia Y, Glaser K et al (2013) Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology 231:1011–1021
5. Bachmann CJ, Manthey T, Kamp-Becker I et al (2013) Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil 34:2551–2563
6. Rani F, Murray ML, Byrne PJ, Wong IC (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002–1009
7. McPheeters ML, Warren Z, Sathe N et al (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127:e1312–e1321
8. American Academy of Child and Adolescent Psychiatry Policy Statement on Comorbidity Treatment in Autism Spectrum Disorders and Intellectual Disabilities. http://www.aacap.org/aacap/Policy_Statements/2013/Comorbidity_Treatment_in_Autism_Spectrum_Disorders_and_Intellectual_Disabilities.aspx. Accessed 11 Jul 2015
9. Stringaris A (2011) Irritability in children and adolescents: a challenge for DSM-5. Eur Child Adolesc Psychiatry 20:61–66
10. National Institute for Health and Care Excellence (2014) Antisocial behaviour and conduct disorders in children and young people. QS59. National Institute for Health and Care Excellence, London
11. Dove D, Warren Z, McPheeters ML et al (2012) Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics 130:717–726
12. Lin J-D (2014) Medical care burden of children with autism spectrum disorders. Rev J Autism Dev Disord 1:242–247
13. Almandil NB, Liu Y, Murray ML et al (2013) Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs 15:139–150
14. National Institute for Health and Care Excellence (2013) Autism: the management and support of children and young people on the autism spectrum. CG 170. National Institute for Health and Care Excellence, London
15. Glover G, Bernard S, Branford D et al (2014) Use of medication for challenging behaviour in people with intellectual disability. Br J Psychiatry 205:6–7
16. Simonoff E, Pickles A, Charman T et al (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47:921–929
17. Every-Palmer S, Howick J (2014) How evidence-based medicine is failing due to biased trials and selective publication. J Eval Clin Pract 20:908–914
18. US Department of Health and Human Services Aripiprazole: Pediatric Labeling Information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=ABILIFY8. Accessed 10 Jul 2015
19. US Department of Health and Human Services Risperidone: Pediatric Labeling Information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=RISPERIDONE. Accessed 10 Jul 2015
20. Taylor E (2013) Pediatric psychopharmacology: too much and too little. World Psychiatry 12:124–125
21. World Health Organisation (2008) Multiaxial classification child and adolescent psychiatric disorders: the ICD-10 classification of mental and behavioural disorders in children and adolescents. WHO, Cambridge
22. Lord C, Rutter M, Goode S et al (1989) Austism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 19:185–212
23. Baird G, Simonoff E, Pickles A et al (2006) Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the special needs and autism project (SNAP). Lancet 368:210–215
24. Goodman R (1997) The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry 38:581–586
25. Wu C-Y, Chang C-K, Robson D et al (2013) Evaluation of smoking status identification using electronic health records and open-text information in a large mental health case register. PLoS ONE 8:e74262
26. Hayes RD, Downs J, Chang C-K et al (2015) The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull 41:644–655
27. Shaffer D, Gould MS, Brasic J et al (1983) A children’s global assessment scale (CGAS). Arch Gen Psychiatry 40:1228–1231
28. Wagner A, Lecavalier L, Arnold LE, Aman MG (2007) Developmental disabilities modification of the children’s global assessment scale. Biol Psychiatry 61:504–511
29. Department for Communities and Local Government English indices of deprivation 2010: technical report
30. Goodman R (2001) Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry 40:1337–1345
31. Rubin DM, Feudtner C, Localio R, Mandell DS (2009) State variation in psychotropic medication use by foster care children with autism spectrum disorder. Pediatrics 124:e305–e312
32. Garland AF, Brookman-Frazee L, Gray E (2013) The role of parent characteristics in community-based medication treatment for children with disruptive behavior problems. Community Ment Health J 49:507–514
33. Leslie LK, Weckerly J, Landsverk J, Hough RL (2003) Racial/ethnic differences in the use of psychotropic medication in high-risk children and adolescents. J Am Acad Child Adolesc Psychiatry 42:1433–1442
34. Zuvekas SH, Vitiello B, Norquist GS (2006) Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 163:579–585
35. Drilea SK, Jowers K, Lichtenstein C et al (2013) Psychotropic medication use and clinical outcomes among children and adolescents receiving system of care services. J Child Adolesc Psychopharmacol 23:36–43
36. Frazier TW, Shattuck PT, Narendorf SC et al (2011) Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 21:571–579
37. Aman MG, Kasper W, Manos G (2010) Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol 20:415–422
38. Hawley CJ, Littlechild B, Sivakumaran T (2006) Structure and content of risk assessment proformas in mental healthcare. J Ment Health 15:437–448
39. Waris P, Lindberg N, Kettunen K, Tani P (2013) The relationship between Asperger’s syndrome and schizophrenia in adolescence. Eur Child Adolesc Psychiatry 22:217–223
40. Kyriakopoulos M, Stringaris A, Manolesou S et al (2015) Determination of psychosis-related clinical profiles in children with autism spectrum disorders using latent class analysis. Eur Child Adolesc Psychiatry 24:301–307
41. Kumra S, Jacobsen LK, Lenane M et al (1998) “Multidimensionally impaired disorder”: is it a variant of very early-onset schizophrenia? J Am Acad Child Adolesc Psychiatry 37:91–99
42. Stayer C, Sporn A, Gogtay N et al (2005) Multidimensionally impaired: the good news. J Child Adolesc Psychopharmacol 15:510–519
43. McDougle CJ, Scahill L, Aman MG et al (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142–1148